SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A Q3 earnings beat, stronger-than-expected Q4 guidance, and expanded buyback authorization drove TTDs sharp move, but the stock reversed during the earnings call. Traders debated whether short-covering could support further gains, while others focused on flat-to-declining revenue, margin pressure, and cautious management commentary.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A disappointing Q3 reportwith an unexpected loss, weaker profit outlook, margin compression and a sequential subscriber declinehas driven HIMS lower despite strong revenue growth. Traders are debating whether those near-term pressures outweigh international expansion and potential growth from the Peptides+ launch and Andrew Hubermans board role.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines quarterly results beat expectations and revenue guidance improved, but the stocks sharp post-report volatility has traders focused on margin compression, weaker-than-hoped profit conversion, debt, and accounting adjustments. Some see the selloff as an overreaction to a solid growth quarter, while others view the margins and balance-sheet risks as legitimate concerns.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riots 15-year lease of its Corsicana campus to a frontier AI lab, alongside better-than-expected quarterly results, has focused attention on its shift from Bitcoin mining toward AI data-center infrastructure. Bulls view the contract as validation of that pivot, while skeptics point to financing, permitting and construction risks before the future lease revenue arrives.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is drawing attention around its earnings report, with traders saying results beat expectations but expressing frustration over the stocks weak reaction. Some view the pullback as a buying opportunity, while others remain concerned about the persistent selling.

Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.

Iambic Therapeutics Inc.

Traders are highlighting reportedly promising updated IAM1363 data, particularly in patients previously treated with HER2 therapies, alongside a disclosed share purchase by a director-affiliated fund. Discussion also reflects sharp post-IPO volatility, with bullish views on Iambics biotech and AI-drug-discovery prospects balanced by skepticism about the stocks swings.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WYFI is drawing attention amid a sharp, volatile selloff in AI data-center stocks and a rebound that traders are debating. Bulls point to AI capacity demand, the retrofit strategy and potential customer deals, while skeptics focus on dilution, NC-1 execution and financing risks ahead of earnings and further contract updates.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras quarterly results beat expectations, alongside positive Phase 2 progress for its ABCL635 hot-flash treatment and three new programs entering IND-enabling work. Traders largely welcomed the pipeline expansion and strong liquidity, while viewing the results as progress toward AbCellera becoming a clinical-stage drug developer.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Jobys Q3 results beat expectations and lifted its revenue outlook, alongside progress in the final stage of FAA certification and a manufacturing ramp. Bulls see this as evidence of improving commercialization prospects and point to possible short covering, while skeptics remain concerned about certification delays, cash burn, and the path to paying passenger service.

Bonk (BONK) is a cryptocurrency launched in 2022and operates on the Solana platform. Bonk has a current supply of 87,994,300,523,147.75. The last known price of Bonk is 0.00000279 USD and is up 2.20 over the last 24 hours. It is currently trading on 848 active market(s) with $26,011,380.42 traded over the last 24 hours. More information can be found at https://www.bonkcoin.com/.

BONK

Speculation about a BONK rebound is driving attention, with many traders buying dips and anticipating a broader meme-coin or Solana-ecosystem rally; some also point to a possible BonkFun 2.0 relaunch and growing holder counts. Others remain frustrated by BONKs prolonged weakness and question whether the anticipated catalysts will bring a sustained recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP PR Newswire LOS ANGELES, July 6, 2026 LOS ANGELES, July 6, 2026 /PRNewswire...

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (Immutep or the Company) (NASDAQ: IMMP) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming...

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP PR Newswire LOS ANGELES, June 29, 2026 LOS ANGELES, June 29, 2026 /PRNewswire...

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm PR Newswire LOS ANGELES, June 29, 2026 LOS ANGELES, June 29, 2026 /PRNewswire/ -- The...

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm PR Newswire LOS ANGELES, June 22, 2026 LOS ANGELES, June 22, 2026 /PRNewswire/ -- The...

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP PR Newswire LOS ANGELES, June 22, 2026 LOS ANGELES, June 22, 2026 /PRNewswire...

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm PR Newswire LOS ANGELES, June 15, 2026 LOS ANGELES, June 15, 2026 /PRNewswire/ -- The...

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Immutep Limited - ADR

Why Did IMMP Stock Surge 150% In Pre-Market Today?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The FDA issues ODD to therapies showing encouraging results for treating diseases affecting fewer than 200,000 people.</li><li>This comes after a successful trial of the company’s Eftilagimod Alfa, tested with radiotherapy and the immunotherapy drug Keytruda in patients before surgery.</li><li>Last month, a trial for Efti in first-line non-small cell lung cancer was stopped, leading to an 82% intraday plunge in IMMP stock.</li></ul>Shares of Immutep Ltd (IMMP) surged around 150% in pre-market trading on Wednesday, on track for their biggest intraday gains since Dec. 10, 2020, after the biotech firm announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its drug to treat soft tissue sarcoma.The decision is supported by encouraging results from the Phase II EFTISARC-NEO trial, in which Eftilagimod Alfa (Efti) was tested with radiotherapy and the immunotherapy drug Keytruda in patients before surgery. In 38 patients, the study met its primary endpoint, showing a median tumor hyalinization/fibrosis of 51.5%, well above the 35% target. This essentially means that half of the tumor tissue showed signs of being replaced by scar-like tissue.The FDA issues ODD to therapies showing encouraging results for treating diseases affecting fewer than 200,000 people. The designation comes with additional benefits, including regulatory assistance, tax credits, fee waivers, and 7 years of market exclusivity upon approval.<h2 class="st-heading-2">Silver Lining After Phase III TACTI-004 Trial Was Abandoned</h2>In March, Immutep announced that its Phase III TACTI-004 trial of Efti in first-line non-small cell lung cancer will be stopped following an interim review by the Independent Data Monitoring Committee (IDMC), which found that the study was unlikely to meet its goals. Following this decision, Immutep expects its cash runway to extend beyond its earlier guidance of the second quarter (Q2) of 2027.The stock plunged 82% after the March 13 update, dropping below $1 and failing to recover since then. Prior to the update, IMMP shares were placed under a trading halt for five sessions.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on <a href="https://stocktwits.com/symbol/IMMP">IMMP stock</a> flipped to ‘extremely bullish’ from ‘bearish’ a day earlier.One user expects the latest news to lead to new partnerships or even an acquisition.&nbsp;<stembedurl>https://stocktwits.com/joe77w/message/650314490</stembedurl>However, another user said that the Phase III TACTI-004 failure “still defines the long-term trend.”<stembedurl>https://stocktwits.com/Treasuremovers/message/650314616</stembedurl>The stock has crashed around 80% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

Immutep announced that the U.S. FDA granted Orphan Drug Designation for its drug for the treatment of soft-tissue sarcoma.

Why Is This Beaten-Down Biotech Surging 150% In Pre-Market Today?

Immutep LTD ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.80
Prev Close	$3.34
Open	$3.62
Dividend Yield	0.00%
50-Day Moving Average	$4.71
Beta	1.28
Avg. Volume	18,288.35
PE Ratio	-0.52

52-Week High	$70.60
52-Week Low	$2.66
Market Capitalization	$28.01M
EPS (Annual)	-$7.30
Price to Book	0.66
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMMP Fundamentals